Size:
0.44 MB
(PDF)
Rating:
Afatinib lung cancer trial results
Boehringer Ingelheim
Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients
- While not extending overall survival in LUX-Lung 1 trial, new data confirm activity and clinical benefit in advanced non-small cell lung cancer -
Milan, Italy, Ingelheim, Germany - Monday 11 October 2010 – Boehringer Ingelheim announced today promising results from two clinical trials of its investigational cancer compound afatinib (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. Results from the “LUX-Lung 1” trial suggest that afatinib (BIBW 2992) is highly active in late-stage patients with NSCLC1, while in the LUX-Lung 2 phase II trial afatinib demonstrated encouraging activity in advanced NSCLC patients that have a mutated EGF Receptor.
Items: 10
Source for healthcare professionals: www.inoncology.com
* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.
© 2012 Boehringer Ingelheim GmbH. All rights reserved.
|
Terms of use
|
Imprint
Boehringer Ingelheim on
